tetano
Editor, Senior Moderator
J Formos Med Assoc
. 2022 Sep 8;S0929-6646(22)00354-0.
doi: 10.1016/j.jfma.2022.09.004. Online ahead of print.
Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine
Wang-Huei Sheng[SUP] 1 [/SUP], Si-Man Ieong[SUP] 2 [/SUP], Pin-Hung Lin[SUP] 3 [/SUP], Ming-Ju Hsieh[SUP] 4 [/SUP], Hung-Chih Yang[SUP] 5 [/SUP], Ching-Fu Pan[SUP] 3 [/SUP], Tai-Ling Chao[SUP] 6 [/SUP], Sui-Yuan Chang[SUP] 7 [/SUP], Shan-Chwen Chang[SUP] 8 [/SUP]
Affiliations
Abstract
Background/purpose: The efficacy and safety of coronavirus disease 2019 (COVID-19) booster vaccines remain limited. We investigated the immunogenicity and adverse events of the third dose of mRNA vaccines in healthy adults.
Methods: Volunteers vaccinated with two doses of the adenoviral vaccine (ChAdOx1) 12 weeks before were administered with an mRNA COVID-19 vaccine. These were divided into three groups, full-dose mRNA-1273 (group 1); half-dose mRNA-1273 (group 2); and full-dose BNT-162b2 (group 3). Primary outcomes included serum anti-SARS-CoV-2 spike immunoglobulin G (IgG) titers and neutralizing antibody titers against B.1.1.7 (alpha), B.1.617.2 (delta), and B.1.1.529 (omicron) variants. Secondary outcomes included the evaluation of humoral and cellular immunity and vaccine-associated adverse events after the boost.
Results: Totally 300 participants were recruited, and 298 participants were enrolled. For all three groups, an increase in anti-SARS-CoV-2 spike IgG geometric mean titers (30.12- to 71.80-fold) and neutralizing antibody titers against the alpha variant (69.80- to 173.23-folds), delta variant (132.69- to 324.63-folds), and omicron variant (135.36- to 222.37-folds) were observed on day 28. All groups showed robust T- and B-cell responses after boosting. Adverse events were overall mild and transient but with higher prevalence and severity in group 1 participants than in other groups.
Conclusions: Third dose mRNA COVID-19 vaccines markedly enhanced cellular and humoral responses and were safe. Immunological responses and adverse events were higher in individuals receiving the full-dose mRNA-1273 vaccine, followed by a half-dose mRNA-1273 vaccine and BNT-162b2 vaccine.
Keywords: Coronavirus disease 2019 (COVID-19); Immune response; Messenger RNA vaccine; Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2).
. 2022 Sep 8;S0929-6646(22)00354-0.
doi: 10.1016/j.jfma.2022.09.004. Online ahead of print.
Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine
Wang-Huei Sheng[SUP] 1 [/SUP], Si-Man Ieong[SUP] 2 [/SUP], Pin-Hung Lin[SUP] 3 [/SUP], Ming-Ju Hsieh[SUP] 4 [/SUP], Hung-Chih Yang[SUP] 5 [/SUP], Ching-Fu Pan[SUP] 3 [/SUP], Tai-Ling Chao[SUP] 6 [/SUP], Sui-Yuan Chang[SUP] 7 [/SUP], Shan-Chwen Chang[SUP] 8 [/SUP]
Affiliations
- PMID: 36127206
- DOI: 10.1016/j.jfma.2022.09.004
Abstract
Background/purpose: The efficacy and safety of coronavirus disease 2019 (COVID-19) booster vaccines remain limited. We investigated the immunogenicity and adverse events of the third dose of mRNA vaccines in healthy adults.
Methods: Volunteers vaccinated with two doses of the adenoviral vaccine (ChAdOx1) 12 weeks before were administered with an mRNA COVID-19 vaccine. These were divided into three groups, full-dose mRNA-1273 (group 1); half-dose mRNA-1273 (group 2); and full-dose BNT-162b2 (group 3). Primary outcomes included serum anti-SARS-CoV-2 spike immunoglobulin G (IgG) titers and neutralizing antibody titers against B.1.1.7 (alpha), B.1.617.2 (delta), and B.1.1.529 (omicron) variants. Secondary outcomes included the evaluation of humoral and cellular immunity and vaccine-associated adverse events after the boost.
Results: Totally 300 participants were recruited, and 298 participants were enrolled. For all three groups, an increase in anti-SARS-CoV-2 spike IgG geometric mean titers (30.12- to 71.80-fold) and neutralizing antibody titers against the alpha variant (69.80- to 173.23-folds), delta variant (132.69- to 324.63-folds), and omicron variant (135.36- to 222.37-folds) were observed on day 28. All groups showed robust T- and B-cell responses after boosting. Adverse events were overall mild and transient but with higher prevalence and severity in group 1 participants than in other groups.
Conclusions: Third dose mRNA COVID-19 vaccines markedly enhanced cellular and humoral responses and were safe. Immunological responses and adverse events were higher in individuals receiving the full-dose mRNA-1273 vaccine, followed by a half-dose mRNA-1273 vaccine and BNT-162b2 vaccine.
Keywords: Coronavirus disease 2019 (COVID-19); Immune response; Messenger RNA vaccine; Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2).